Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain
NCT05250947 is a phase 1 interventional trial sponsored by Matthew Pingree. As of 18 Nov 2026, it was terminated. It studies Platelet Rich Plasma in Lumbar Spondylosis. The registry lists an enrollment of 4 participants at 1 site in 1 country. The registry lists a start date of 5 Jan 2023 and a primary completion date of 20 May 2024.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05250947 |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Matthew Pingree |
| Enrollment | 4 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Lumbar Spondylosis |
| Drugs | Platelet Rich Plasma |
| Start | 5 Jan 2023 |
| Primary completion | 20 May 2024 |
| Study completion | 20 May 2024 |
| Last update posted | 17 Jul 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Matthew Pingree, MD
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Rochester
Rochester
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05250947
Each answer restates registry values shown on this page.
What is NCT05250947?
NCT05250947 is a phase 1 interventional trial sponsored by Matthew Pingree. It studies Platelet Rich Plasma in Lumbar Spondylosis.
Who leads NCT05250947?
The registry names Matthew Pingree, MD (principal investigator, Mayo Clinic) as the overall official.
Where does NCT05250947 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05250947 study?
The registered drug and biological interventions are Platelet Rich Plasma.
When did NCT05250947 end?
The registry lists a primary completion date of 20 May 2024 and a study completion date of 20 May 2024. The sponsor last updated the record on 17 Jul 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.